Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Veracyte Inc (NQ: VCYT )

20.03 -1.00 (-4.76%)
Streaming Delayed Price Updated: 10:49 AM EDT, May 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Veracyte Inc

< Previous 1 2 3 4 Next >
VCYT Stock Earnings: Veracyte Beats EPS, Beats Revenue for Q1 2024
VCYT stock results show that Veracyte beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Cathie Wood's Ark Invest Dumps $17M In Coinbase Shares As The Exchange Grappled With Disruption Amid Bitcoin Rally
On Wednesday, Cathie Wood-led Ark Invest made a significant move by selling over $17 million worth of Coinbase Global Inc (NASDAQ:COIN) shares. 
Via Benzinga
Cathie Wood's Ark Invest Sheds $9.3M Worth Of Coinbase Shares Amid Bitcoin Rally — Robinhood Stock Also Sold
On Tuesday, Cathie Wood-led Ark Invest adjusted its portfolio, making significant trades. 
Via Benzinga
Cathie Wood's Ark Invest Offloads $6.9M Worth of Coinbase, Robinhood Shares Each Amid Searing Bitcoin Rally — Nvidia Stock Also Shed
On Monday, Cathie Wood-led Ark Invest adjusted its portfolio, notably selling shares of cryptocurrency-related companies such as Robinhood Markets Inc (NASDAQ:HOOD) and Coinbase Global Inc (NASDAQ: 
Via Benzinga
Recap: Veracyte Q4 Earnings
Via Benzinga
Earnings Outlook For Veracyte
Via Benzinga
Veracyte: Q3 Earnings Insights
Via Benzinga
The Latest Analyst Ratings for Veracyte
Via Benzinga
7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff
Although the health innovation space can be a risky environment, undervalued biotech stocks can take some of the edge off. 
Via InvestorPlace
Cathie Wood's Ark Invest Buys Over $92M Worth Of ProShares Bitcoin ETF, Sells Coinbase, Block And Palantir Shares
On Wednesday, Cathie Wood-led Ark Invest made a significant move in the cryptocurrency space, purchasing over $92 million worth of ProShares Bitcoin Strategy ETF (NYSE:BITO). 
Via Benzinga
Topics ETFs
Are You A Trader Or Investor: Biotech Momentum Is Picking Up
ETFs have not helped as portfolio fillers but they can identify trends. We should play this rally out of a biotech bear market. 
Via Talk Markets
Topics ETFs
7 Undervalued Stocks That Analysts Love Right Now
With many investors concerned about what may lie ahead in the market, these potentially de-risked undervalued stocks may be ideal. 
Via InvestorPlace
Here's Why This Little-Known Growth Stock Is a Buy
Analysts think this genomic test maker could have major upside in the next year. 
Via The Motley Fool
Looking Into Veracyte's Return On Capital Employed
Via Benzinga
Recap: Veracyte Q1 Earnings
Via Benzinga
A Preview Of Veracyte's Earnings
Via Benzinga
Earnings Scheduled For February 22, 2024
Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is likely to report quarterly earnings at $0.28 per share on revenue of $260.00 million. 
Via Benzinga
Earnings Scheduled For November 7, 2023
Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings for its third quarter. 
Via Benzinga
Veracyte Stock Is Volatile After-Hours - Here's Why
Veracyte, Inc. (NASDAQ: VCYT) shares are volatile after-hours on Wednesday after the company announced that new data from a phase 3 trial validates the value of the Decipher Prostate Genomic Classifier... 
Via Benzinga
Is This Underfollowed Genetic Diagnostics Stock a Buy for Growth Investors?
The genetic test maker is rapidly increasing test volumes. 
Via The Motley Fool
Looking for Biotech AI Stocks? 3 Names That Will Benefit From the AI Boom
AI is changing the face of biotechnology and drug discovery. Don't miss out on the next big boom in biotech, here are 3 stocks to consider. 
Via InvestorPlace
Market Mixes It Up With A Broad Rally
Biotech stocks remain sluggish but the longer-term outlook for breakthrough therapies - gene therapy, obesity, CNS, RNA - remain positive. 
Via Talk Markets
Time To Play Small Cap Life Science Stocks
The overall market sentiment has been hit hard by MACRO concerns. The dominating narrative is the Fed and the Debt Ceiling. 
Via Talk Markets
Something Happened In Biotech Last Week
Biotech stocks were more constructive last week with some sharp moves up. 
Via Talk Markets
Earnings Scheduled For May 4, 2023
Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is estimated to report quarterly loss at $1.83 per share on revenue of $104.21 million. 
Via Benzinga
Biotech And Life Science Trades: Q1 2023 Performance By The Numbers
Despite a strong month and a great finish to the quarter, many traders remain cautious about the market. It’s been a volatile time after the collapse of Silicon Valley Bank, but the first quarter of... 
Via Talk Markets
7 Biotech Stocks That Could Be the Next Big Thing
Although speculation might be a tough call at this juncture, these biotech stocks and their underlying science might be compelling enough. 
Via InvestorPlace
Double-Digit Sales Growth: Is This Stock a Convincing Buy for Growth Investors?
This diagnostics test maker has held up well over the last year. 
Via The Motley Fool
SMID Cap Life Science Update: Are You An Investor Or Trader?
Despite choppy trading, there is an upward tilt to life science stocks since the 9/26/22 lows. 
Via Talk Markets
Earnings Scheduled For February 22, 2023
Companies Reporting Before The Bell • Rio Tinto (NYSE:RIO) is projected to report earnings for its Fiscal Year 2022. 
Via Benzinga
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.